Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Impact · against what's priced in

Alamar Biosciences shows strong operational momentum with 82% YoY revenue growth and a significant shift toward high-margin consumables. The acceleration of recurring revenue and the ability to deploy new assays across the existing installed base provide a scalable growth path.

ALMR+0.60

No priced-in read yet

In context

The company's 82% YoY revenue growth to $29.4M and 147% surge in consumables sales demonstrate rapid market adoption and improving revenue quality via 60% gross margins.

Read from the article alone

• biotech
• revenue growth
• healthcare
• ALMR
• biomarkers
• consumables
• diagnostics
• gross margin
• proteomics

Search tags